

All information is as of 04/20/2018 and is subject to change.

Equity	CUSIPs		Fee CUSIPs		Ticker	Term
Target Strategy Portfolios — U.S. Equity						
Dow® Target 10, April 2018	30307C	803 (c) 811 (r)	30307C	829 (c) 837 (r)	FKYPMX	13 Month
Dow® Target 5, 2nd Qtr 2018	30307D	108 (c) 116 (r)	30307D	124 (c) 132 (r)	FQLJTX	15 Month
Dow® Target Dividend, 2nd Qtr 2018	30307D	140 (c) 157 (r)	30307D	165 (c) 173 (r)	FTRUAX	15 Month
S&P Dividend Aristocrats Target 25, 2nd Qtr 2018	30307D	223 (c) 231 (r)	30307D	249 (c) 256 (r)	FKTNEX	15 Month
S&P Target 24, 2nd Qtr 2018	30307D	264 (c) 272 (r)	30307D	280 (c) 298 (r)	FMRTGX	15 Month
S&P Target SMid 60, 2nd Qtr 2018	30307D	462 (c) 470 (r)	30307D	488 (c) 496 (r)	FWREMX	15 Month
Target Diversified Dividend, 2nd Qtr 2018	30307D	306 (c) 314 (r)	30307D	322 (c) 330 (r)	FOADWX	15 Month
Target Growth, 2nd Qtr 2018	30307D	546 (c) 553 (r)	30307D	561 (c) 579 (r)	FPBYGX	15 Month
Target High Quality Dividend, 2nd Qtr 2018	30307C	720 (c) 738 (r)	30307C	746 (c) 753 (r)	FYRGTX	15 Month
Value Line® Target 25, 2nd Qtr 2018	30307D	421 (c) 439 (r)	30307D	447 (c) 454 (r)	FNEKLX	15 Month
Value Line® Target Safety 30, 2nd Qtr 2018	30307C	761 (c) 779 (r)	30307C	787 (c) 795 (r)	FVELZX	15 Month
Target Strategy Portfolios — Foreign/Global						
European Target High Quality Dividend, 2nd Qtr 2018	30307C	647 (c) 654 (r)	30307C	662 (c) 670 (r)	FTRNLX	15 Month
Global Target 15, 2nd Qtr 2018	30307D	181 (c) 199 (r)	30307D	207 (c) 215 (r)	FEBPUX	15 Month
Target Global Dividend Leaders, 2nd Qtr 2018	30307D	389 (c) 397 (r)	30307D	405 (c) 413 (r)	FNRTAX	15 Month
Target Strategy Portfolios — Multi-Strategy						
Target Diversified Global Allocation, 2nd Qtr 2018	30307C	605 (c) 613 (r)	30307C	621 (c) 639 (r)	FKROZX	15 Month
Target Dividend Blend, 2nd Qtr 2018	30307C	688 (c) 696 (r)	30307C	704 (c) 712 (r)	FAVMCX	15 Month
Target Double Play, 2nd Qtr 2018	30307D	348 (c) 355 (r)	30307D	363 (c) 371 (r)	FMUKBX	15 Month
Target Focus Four, 2nd Qtr 2018	30307D	504 (c) 512 (r)	30307D	520 (c) 538 (r)	FWYNPX	15 Month
Target Triad, 2nd Qtr 2018	30307D	587 (c) 595 (r)	30307D	603 (c) 611 (r)	FBJNCX	15 Month
Target VIP, 2nd Qtr 2018	30307D	629 (c) 637 (r)	30307D	645 (c) 652 (r)	FBUETX	15 Month
Sector/Industry Portfolios						
Aerospace & Defense, 20	30307F	582 (c) 590 (r)	30307F	608 (c) 616 (r)	FTWINX	2 Year
AI & Robotics Opportunity, 3	30307G	267 (c) 275 (r)	30307G	283 (c) 291 (r)	FJYBBX	15 Month
Banking Opportunity, 29	30307B	268 (c) 276 (r)	30307B	284 (c) 292 (r)	FQNRAX	15 Month
Biotechnology, 40	30307E	403 (c) 411 (r)	30307E	429 (c) 437 (r)	FVRCUX	2 Year
Cloud Computing, 20	30307C	340 (c) 357 (r)	30307C	365 (c) 373 (r)	FHOERX	2 Year
Defensive Equity, 44	30307B	227 (c) 235 (r)	30307B	243 (c) 250 (r)	FSTUDX	2 Year
E-Commerce Opportunity, 3	30307G	309 (c) 317 (r)	30307G	325 (c) 333 (r)	FYBUHX	15 Month
Energy Opportunity, 1	30307H	224 (c) 232 (r)	30307H	240 (c) 257 (r)	FVRYBX	15 Month
Energy Select, 67	30307E	148 (c) 155 (r)	30307E	163 (c) 171 (r)	FCRJMX	2 Year
Financials Opportunity, 1	30307H	265 (c) 273 (r)	30307H	281 (c) 299 (r)	FDALHX	15 Month
Financials Select, 63	30306Y	780 (c) 798 (r)	30306Y	806 (c) 814 (r)	FSNYCX	2 Year
Global Commodities, 33	30307B	508 (c) 516 (r)	30307B	524 (c) 532 (r)	FZQRBX	2 Year
Health Care Opportunity, 3	30306X	782 (c) 790 (r)	30306X	808 (c) 816 (r)	FZLHUX	15 Month
Health Care Select, 49	30307A	104 (c) 112 (r)	30307A	120 (c) 138 (r)	FLSMCX	2 Year
Homebuilders Recovery Select, 19	30307H	141 (c) 158 (r)	30307H	166 (c) 174 (r)	FGREAX	2 Year
Innovative Transaction & Process, 1	30307E	684 (c) 692 (r)	30307E	700 (c) 718 (r)	FRLBJX	15 Month
Richard Bernstein Advisors Tactical Series, American Industrial Renaissance®, 2018-1	30307F	822 (c) 830 (r)	30307F	848 (c) 855 (r)	FGWMLX	2 Year
SMid Biotechnology, 1	30307B	664 (c) 672 (r)	30307B	680 (c) 698 (r)	FHTUNX	15 Month
Technology Opportunity, 4	30307H	422 (c) 430 (r)	30307H	448 (c) 455 (r)	FRUSMX	15 Month
Technology Select, 68	30307A	427 (c) 435 (r)	30307A	443 (c) 450 (r)	FQIAJX	2 Year
U.S. Energy Independence, 18	30307F	228 (c) 236 (r)	30307F	244 (c) 251 (r)	FBAVDX	2 Year
U.S. Infrastructure, 14	30307C	845 (c) 852 (r)	30307C	860 (c) 878 (r)	FNIYCX	2 Year
Utilities Select, 46	30306Y	822 (c) 830 (r)	30306Y	848 (c) 855 (r)	FJTVMX	2 Year
Water Utility & Infrastructure Select, 49	30307E	189 (c) 197 (r)	30307E	205 (c) 213 (r)	FBEWLX	2 Year
Foreign/Global Portfolios						
Emerging Markets Strength, 40	30307G	622 (c) 630 (r)	30307G	648 (c) 655 (r)	FPLBUX	2 Year
International Capital Strength Opportunity, 4	30307E	601 (c) 619 (r)	30307E	627 (c) 635 (r)	FZOIPX	15 Month
International Capital Strength, 37	30306X	386 (c) 394 (r)	30306X	402 (c) 410 (r)	FTUJAX	2 Year
Japan, 11	30307C	464 (c) 472 (r)	30307C	480 (c) 498 (r)	FVORWX	15 Month
Strategic International Opportunity, 4	30307G	341 (c) 358 (r)	30307G	366 (c) 374 (r)	FCIFAX	15 Month

All information is as of 04/20/2018 and is subject to change.

Equity	CUSIPs		Fee CUSIPs		Ticker	Term
Theme/Specialty Portfolios						
American Agenda, 4	30307A	740 (c) 757 (r)	30307A	765 (c) 773 (r)	FHLWCX	2 Year
Capital Strength Opportunity, 4	30307C	100 (c) 118 (r)	30307C	126 (c) 134 (r)	FJCYHX	15 Month
Capital Strength, 42	30307G	143 (c) 150 (r)	30307G	168 (c) 176 (r)	FLIBNX	2 Year
Content Leaders, 8	30307B	383 (c) 391 (r)	30307B	409 (c) 417 (r)	FBWENX	15 Month
Core Holdings Growth, Spring 2018	30307A	146 (c) 153 (r)	30307A	161 (c) 179 (r)	FQTYAX	5 Year
Corporate Tax Reform, 5	30307A	625 (c) 633 (r)	30307A	641 (c) 658 (r)	FCLIGX	2 Year
Cybersecurity, 11	30307C	423 (c) 431 (r)	30307C	449 (c) 456 (r)	FCNLEX	2 Year
Cyclical Strength, 21	30307D	827 (c) 835 (r)	30307D	843 (c) 850 (r)	FVAILX	2 Year
Dorsey Wright Relative Strength Top 50, 30	30307C	142 (c) 159 (r)	30307C	167 (c) 175 (r)	FDNZJX	15 Month
Dow Jones Global Titans, 24	30307F	624 (c) 632 (r)	30307F	640 (c) 657 (r)	FGYALX	2 Year
Election Portfolio, 2016 Series 6	30306Y	582 (c) 590 (r)	30306Y	608 (c) 616 (r)	FPMCAX	2 Year
ESG Impact Opportunity, 2	30307B	540 (c) 557 (r)	30307B	565 (c) 573 (r)	FYRKPX	15 Month
Innovative Technology, 18	30307F	780 (c) 798 (r)	30307F	806 (c) 814 (r)	FPHAOX	2 Year
Low Volatility, 11	30307F	707 (c) 715 (r)	30307F	723 (c) 731 (r)	FVLNCX	15 Month
Market Strength Allocation Opportunity, 4	30307C	225 (c) 233 (r)	30307C	241 (c) 258 (r)	FMPJUX	15 Month
Market Strength Allocation Select, 31	30307G	424 (c) 432 (r)	30307G	440 (c) 457 (r)	FZOHRX	2 Year
Mega-Cap, 48	30307F	541 (c) 558 (r)	30307F	566 (c) 574 (r)	FGKINX	2 Year
Nasdaq Factor Dogs Opportunity, 2	30307A	666 (c) 674 (r)	30307A	682 (c) 690 (r)	FYZBZX	15 Month
Sabrient Baker's Dozen, April 2018	30307G	663 (c) 671 (r)	30307G	689 (c) 697 (r)	FAMNJX	13 Month
Sabrient Defensive Equity, 15	30307B	425 (c) 433 (r)	30307B	441 (c) 458 (r)	FZOMBX	15 Month
Sabrient Rising Rate, 7	30307A	542 (c) 559 (r)	30307A	567 (c) 575 (r)	FEHARX	2 Year
Sabrient Small Cap Growth, 18	30307E	726 (c) 734 (r)	30307E	742 (c) 759 (r)	FCRDLX	15 Month
SMid Capital Strength Opportunity, 4	30307E	643 (c) 650 (r)	30307E	668 (c) 676 (r)	FRJMQX	15 Month
SMid Capital Strength, 37	30306X	428 (c) 436 (r)	30306X	444 (c) 451 (r)	FRJTNX	2 Year
Tactical Alpha, 16	30307F	426 (c) 434 (r)	30307F	442 (c) 459 (r)	FHLPRX	15 Month
U.S. Revenue, 11	30306F	609 (c) 617 (r)	30306F	625 (c) 633 (r)	FTLKPX	2 Year
Asset Allocation						
40/60 Strategic Allocation, 2nd Qtr 2018	30307E	767 (c) 775 (r)	30307E	783 (c) 791 (r)	FPKLDX	15 Month
60/40 Strategic Allocation, 2nd Qtr 2018	30307E	809 (c) 817 (r)	30307E	825 (c) 833 (r)	FQRNDX	15 Month
75/25 Strategic Allocation, 2nd Qtr 2018	30307E	841 (c) 858 (r)	30307E	866 (c) 874 (r)	FBSWTX	15 Month
Diversified Equity Strategic Allocation, 2nd Qtr 2018	30307C	563 (c) 571 (r)	30307C	589 (c) 597 (r)	FWTGPX	15 Month
Diversified Fixed Income ETF, 34	30307F	103 (c) 111 (r)	30307F	129 (c) 137 (r)	FPZYQX	15 Month
ETF Growth and Income, April 2018	30307G	226 (c) 234 (r)	30307G	242 (c) 259 (r)	FEYAJX	15 Month
First Trust® ETF Allocation, 24	30307F	145 (c) 152 (r)	30307F	160 (c) 178 (r)	FEVOLX	2 Year
Income						
Equity Income Portfolios						
Automated Quantitative Analysis, 16	30306F	849 (c) 856 (r)	30306F	864 (c) 872 (r)	FKMGAX	2 Year
Brookmont Equity Dividend, 15	30308B	465 (c) 473 (r)	30308B	481 (c) 499 (r)	FDRVTX	15 Month
Covered Call Select Closed-End, 65	30305Y	740 (c) 757 (r)	30305Y	765 (c) 773 (r)	FILUEX	2 Year
Deep Value Dividend Opportunity, 4	30307H	380 (c) 398 (r)	30307H	406 (c) 414 (r)	FSMCZX	15 Month
Deep Value Dividend, 18	30307A	781 (c) 799 (r)	30307A	807 (c) 815 (r)	FBNERX	2 Year
Diversified Income & Growth, Spring 2018	30306F	807 (c) 815 (r)	30306F	823 (c) 831 (r)	FNSPTX	5 Year
Dividend & Income Select Closed-End, 65	30307H	505 (c) 513 (r)	30307H	521 (c) 539 (r)	FJTMRX	2 Year
Dividend Edge, 10	30307E	106 (c) 114 (r)	30307E	122 (c) 130 (r)	FIWGVX	15 Month
Dividend Growth, 21	30307E	247 (c) 254 (r)	30307E	262 (c) 270 (r)	FBHEOX	5 Year
Dividend Strength Opportunity, 4	30307E	288 (c) 296 (r)	30307E	304 (c) 312 (r)	FHSKDX	15 Month
Dividend Strength, 39	30306Y	467 (c) 475 (r)	30306Y	483 (c) 491 (r)	FTPUEX	2 Year
Dorsey Wright Relative Strength Dividend, 30	30307E	569 (c) 577 (r)	30307E	585 (c) 593 (r)	FCWKMX	15 Month
Equity Closed-End, 48	30307F	384 (c) 392 (r)	30307F	400 (c) 418 (r)	FYPBWVX	2 Year
Equity Income Opportunity, 3	30306Y	624 (c) 632 (r)	30306Y	640 (c) 657 (r)	FJLYVX	15 Month
Equity Income Select, 56	30307A	823 (c) 831 (r)	30307A	849 (c) 856 (r)	FENIUX	2 Year
Equity Income, 59	30307B	466 (c) 474 (r)	30307B	482 (c) 490 (r)	FIBPRX	5 Year
European Deep Value Dividend, 18	30306G	789 (c) 797 (r)	30306G	805 (c) 813 (r)	FTOIAX	2 Year

All information is as of 04/20/2018 and is subject to change.

Income	CUSIPs		Fee CUSIPs		Ticker	Term
<u>Equity Income Portfolios Continued</u>						
Global Deep Value Dividend, 18	30307F	665 (c) 673 (r)	30307F	681 (c) 699 (r)	FCYOPX	15 Month
Global Dividend, 54	30307B	102 (c) 110 (r)	30307B	128 (c) 136 (r)	FQWMJX	2 Year
Global Equity Income Closed-End, 58	30306G	623 (c) 631 (r)	30306G	649 (c) 656 (r)	FALBEX	2 Year
High Dividend Equity Allocation, 27	30307E	320 (c) 338 (r)	30307E	346 (c) 353 (r)	FYTWNX	2 Year
High Dividend Equity Opportunity, 4	30308B	507 (c) 515 (r)	30308B	523 (c) 531 (r)	FQNVDX	15 Month
High Dividend Equity, 35	30307A	385 (c) 393 (r)	30307A	401 (c) 419 (r)	FLAEX	2 Year
Income Dividend Equity Allocation (IDEA), 16	30307H	463 (c) 471 (r)	30307H	489 (c) 497 (r)	FTZYNX	2 Year
International High Dividend Equity, 33	30307F	509 (c) 517 (r)	30307F	525 (c) 533 (r)	FZDVXX	2 Year
Nasdaq® Dividend Achievers 25, 11	30306F	526 (c) 534 (r)	30306F	542 (c) 559 (r)	FDAERX	2 Year
REIT Growth & Income Select, 45	30307E	361 (c) 379 (r)	30307E	387 (c) 395 (r)	FTLQBX	2 Year
Richard Bernstein Advisors Global Dividend Kings®, 26	30307G	382 (c) 390 (r)	30307G	408 (c) 416 (r)	FVGTMX	2 Year
Richard Bernstein Advisors Quality Income, 28	30306G	540 (c) 557 (r)	30306G	565 (c) 573 (r)	FNTGYX	15 Month
S&P International Dividend Aristocrats, 1st Qtr 2018	30306G	664 (c) 672 (r)	30306G	680 (c) 698 (r)	FURESX	15 Month
Sabrient Dividend, 22	30306Y	541 (c) 558 (r)	30306Y	566 (c) 574 (r)	FRNUTX	2 Year
Select DSIP, 2nd Qtr 2018	30307F	186 (c) 194 (r)	30307F	202 (c) 210 (r)	FQPLEX	15 Month
SMid High Dividend, 29	30307B	144 (c) 151 (r)	30307B	169 (c) 177 (r)	FONLDX	2 Year
Strategic Dividend Select, 32	30307E	486 (c) 494 (r)	30307E	502 (c) 510 (r)	FRUGNX	2 Year
Technology Dividend, 25	30307B	748 (c) 755 (r)	30307B	763 (c) 771 (r)	FHBNVX	2 Year
U.S. Equity Closed-End Portfolio, 26	30306X	469 (c) 477 (r)	30306X	485 (c) 493 (r)	FPNCMX	2 Year
<u>Taxable Income Portfolios</u>						
Global Bond Income Closed-End, 28	30306Y	749 (c) 756 (r)	30306Y	764 (c) 772 (r)	FBTZPX	2 Year
High-Yield Income Closed-End, 81	30307F	343 (c) 350 (r)	30307F	368 (c) 376 (r)	FGALDX	2 Year
Investment Grade Select Closed-End & ETF, 5	30306G	706 (c) 714 (r)	30306G	722 (c) 730 (r)	FNSYGX	2 Year
Limited Duration Fixed Income ETF, 24	30307G	549 (c) 556 (r)	30307G	564 (c) 572 (r)	FMCRRX	2 Year
Preferred Income Opportunity, 8	30306Y	269 (c) 277 (r)	30306Y	285 (c) 293 (r)	FKSHPX	15 Month
Preferred Income, 94	30307C	183 (c) 191 (r)	30307C	209 (c) 217 (r)	FNIRCX	2 Year
Senior Loan & Limited Duration Closed-End, 80	30307G	747 (c) 754 (r)	30307G	762 (c) 770 (r)	FNUJXX	2 Year
Senior Loan & Limited Duration Opportunities Closed-End, 53	30307D	660 (c) 678 (r)	30307D	686 (c) 694 (r)	FCPYGX	15 Month
Senior Loan Closed-End and ETF, 21	30306Y	707 (c) 715 (r)	30306Y	723 (c) 731 (r)	FGSIAX	2 Year
Senior Loan Select Closed-End, 30	30307A	187 (c) 195 (r)	30307A	203 (c) 211 (r)	FYERQX	2 Year
Stonebridge Preferred Income, 17	30307E	445 (c) 452 (r)	30307E	460 (c) 478 (r)	FLACIX	2 Year
Strategic Income Closed-End, 66	30307B	623 (c) 631 (r)	30307B	649 (c) 656 (r)	FVIKAX	2 Year
Tactical Income Opportunity, 4	30307C	381 (c) 399 (r)	30307C	407 (c) 415 (r)	FHBWZX	15 Month
Tactical Income, 51	30306X	188 (c) 196 (r)	30306X	204 (c) 212 (r)	FERGWX	2 Year
<u>Tax-Free Income Portfolios</u>						
California Municipal Income Select Closed-End, 65	30307A	500 (c) 518 (r)	30307A	526 (c) 534 (r)	FDKMOX	2 Year
Municipal Advantage Closed-End and ETF, 47	30307D	785 (c) 793 (r)	30307D	801 (c) 819 (r)	FMGHBX	2 Year
Municipal Income Closed-End, 73	30306Y	665 (c) 673 (r)	30306Y	681 (c) 699 (r)	FNUYOX	5 Year
Municipal Income Opportunities Closed-End, 48	30307B	300 (c) 318 (r)	30307B	326 (c) 334 (r)	FHQDRX	15 Month
Municipal Income Select, Closed-End, 94	30307G	820 (c) 838 (r)	30307G	846 (c) 853 (r)	FKBEMX	2 Year
New Jersey Municipal Income Select Closed-End, 60	30307G	788 (c) 796 (r)	30307G	804 (c) 812 (r)	FAQRSX	2 Year
New York Municipal Income Select Closed-End, 47	30308C	307 (c) 315 (r)	30308C	323 (c) 331 (r)	FOIHSX	2 Year
Tax-Advantaged Municipal Closed-End, 53	30306D	620 (c) 638 (r)	30306D	646 (c) 653 (r)	FJYBZX	2 Year
<u>Hybrid Portfolios</u>						
7Twelve Balanced Portfolio Series	30306X	345 (c) 352 (r)	30306X	360 (c) 378 (r)	FNCMQX	15 Month
Alternative Income, 27	30307F	467 (c) 475 (r)	30307F	483 (c) 491 (r)	FEYJSX	2 Year
Balanced Income Equity and ETF Opportunity, 4	30307H	786 (c) 794 (r)	30307H	802 (c) 810 (r)	FAMIBX	15 Month
Balanced Income Equity and ETF, 31	30307H	588 (c) 596 (r)	30307H	604 (c) 612 (r)	FONYCX	2 Year
Balanced Income Opportunity, 4	30307F	749 (c) 756 (r)	30307F	764 (c) 772 (r)	FEZKRX	15 Month
Balanced Income Select, 75	30307F	301 (c) 319 (r)	30307F	327 (c) 335 (r)	FTDVLX	2 Year
Balanced Income, 61	30307F	269 (c) 277 (r)	30307F	285 (c) 293 (r)	FYZMOX	5 Year
Capital Strength Buy-Write, 38	30307E	221 (c)	30307E	239 (c)	FQTMXX	2 Year
Core Three Closed-End Allocation, 34	30308B	549 (c) 556 (r)	30308B	564 (c) 572 (r)	FYBDLX	2 Year
Diversified High Income Closed-End, 32	30308B	705 (c) 713 (r)	30308B	721 (c) 739 (r)	FMELDX	2 Year

All information is as of 04/20/2018 and is subject to change.

Income	CUSIPs		Fee CUSIPs		Ticker	Term
Hybrid Portfolios Continued						
Income Allocation Closed-End, 2nd Qtr 2018	30307C	522 (c) 530 (r)	30307C	548 (c) 555 (r)	FQLDNX	15 Month
Inflation Hedge, 37	30307H	307 (c) 315 (r)	30307H	323 (c) 331 (r)	FVTOJX	2 Year
Interest Rate Hedge and ETF, 20	30307G	507 (c) 515 (r)	30307G	523 (c) 531 (r)	FIOKJX	2 Year
Interest Rate Hedge Opportunity, 4	30307B	185 (c) 193 (r)	30307B	201 (c) 219 (r)	FVLGTX	15 Month
Interest Rate Hedge, 117	30307G	184 (c) 192 (r)	30307G	200 (c) 218 (r)	FMQZHX	2 Year
MLP Closed-End Fund and Energy, 59	30307H	182 (c) 190 (r)	30307H	208 (c) 216 (r)	FVICPX	2 Year
MLP Closed-End, 20	30307A	229 (c) 237 (r)	30307A	245 (c) 252 (r)	FWEBXS	2 Year
Multi-Sector Income, 39	30306X	824 (c) 832 (r)	30306X	840 (c) 857 (r)	FAVKMX	15 Month
Municipal Income and Dividend Growers, 13	30306G	748 (c) 755 (r)	30306G	763 (c) 771 (r)	FBWUZX	2 Year
Senior Loan and Dividend Growers, 18	30307H	109 (c) 117 (r)	30307H	125 (c) 133 (r)	FNLGBX	2 Year
Strategic Income Advantage Opportunity, Closed-End, 6	30308B	424 (c) 432 (r)	30308B	440 (c) 457 (r)	FPLDAX	15 Month
Strategic Income Advantage Select Closed-End, 74	30307H	547 (c) 554 (r)	30307H	562 (c) 570 (r)	FECRIX	2 Year
Strategic Income Select Closed-End, 34	30308B	788 (c) 796 (r)	30308B	804 (c) 812 (r)	FRBVHX	2 Year

Unit Investment Trust Features – A unit investment trust (UIT) is a pooled investment vehicle in which a fixed portfolio of stocks, bonds or other securities is selected by the sponsor, deposited into the trust, and held for a predetermined period of time. Investors purchase units of a trust, which represent an undivided ownership interest in the assets contained in the trust. A UIT follows a buy and hold strategy and investors should consider their ability to hold a trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan. Units of a trust can be liquidated daily at the redemption price, which may be more or less than the original purchase price.

Risk Considerations – There are risks involved with investing in UITs, including the potential loss of money. There is no assurance an unmanaged unit investment trust will achieve its investment objective(s). Please be aware that each UIT listed is subject to various risks which, depending on the investment objective, may include risks such as concentration, sector, interest rate, credit, fixed-income or equity investing, options, high-yield securities, commodities, and foreign and emerging markets. In addition, the value of the securities held by a trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers. For a complete description of relative risks for a specific trust please obtain and carefully read the prospectus.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA and the Internal Revenue Code. First Trust has no knowledge of and has not been provided any information regarding any investor. Financial advisors must determine whether particular investments are appropriate for their clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment risks independently and is responsible for exercising independent judgment with respect to its retirement plan clients.

You should consider a trust's investment objective, risks, and charges and expenses carefully before investing. Contact your financial advisor or call First Trust Portfolios L.P. at 1-800-621-1675 to request a prospectus, which contains this and other information about a trust. Read it carefully before you invest.

The "Dow Jones Industrial Average" and the Dow Jones U.S. Select Dividend IndexSM are products of S&P Dow Jones Indices LLC ("SPDJI"), and have been licensed for use by First Trust Advisors L.P. Standard & Poor's[®] and S&P[®] are registered trademarks of Standard & Poor's Financial Services LLC ("S&P"); DJIA[®], The Dow[®], Dow Jones[®], and Dow Jones Industrial Average are trademarks of Dow Jones Trademark Holdings LLC ("Dow Jones"); and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by First Trust Advisors L.P. The Dow Target 10, Dow Target 5, Dow Target Dividend, Target Double Play, Target Focus Four and Target VIP portfolios, are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates, and none of such parties make any representation regarding the advisability of investing in such products.

"Standard & Poor's", "S&P", "S&P 500", "S&P MidCap 400", "S&P SmallCap 600", "S&P Dividend Aristocrats", and "S&P International Dividend Aristocrats", are registered trademarks of Standard & Poor's Financial Services LLC ("S&P") and have been licensed for use by First Trust Portfolios L.P. The S&P Dividend Aristocrats Target 25, S&P International Dividend Aristocrats, S&P Target 24, S&P Target SMid 60, Target Focus Four and Target VIP portfolios are not sponsored, endorsed, sold, or promoted by Standard & Poor's and Standard & Poor's makes no representation regarding the advisability of investing in such products.

NYSE[®] is a registered service mark of, and NYSE International 100 IndexSM is a service mark of, New York Stock Exchange, Inc. ("NYSE") and have been licensed for use for certain purposes by First Trust Portfolios L.P. The Target Triad and Target Focus Four portfolios, based on the NYSE International 100 IndexSM, are not sponsored, endorsed, sold, or promoted by NYSE and NYSE makes no representation regarding the advisability of investing in such products.

Nasdaq[®] and NASDAQ US Broad Dividend Achievers IndexSM are registered trademarks of Nasdaq, Inc. (which with its affiliates are the Corporations) and are licensed for use by First Trust Portfolios L.P. The Nasdaq Factor Dogs Opportunity and Nasdaq[®] Dividend Achievers portfolios have not been passed on by the Corporations as to its legality or suitability. The Nasdaq Factor Dogs Opportunity and the Nasdaq[®] Dividend Achievers portfolios are not issued, endorsed, sold, or promoted by the Corporations. **THE CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THE PORTFOLIO.**

The Dow Jones Global Titans 50SM Index is a product of S&P Dow Jones Indices LLC or its affiliates ("SPDJI") and Global Titans[®] is a registered trademark of SPDJI. Both have been licensed for use by First Trust Portfolios L.P. Standard & Poor's[®] and S&P[®] are registered trademarks of Standard & Poor's Financial Services LLC ("S&P"); Dow Jones[®] is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"); and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by First Trust Portfolios L.P. The Dow Jones Global Titans Portfolio is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, or their respective affiliates, and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the Dow Jones Global Titans 50SM Index.

"Value Line," "The Value Line Investment Survey," and "Timeliness" are trademarks or registered trademarks of Value Line, Inc. ("Value Line") and have been licensed for use for certain purposes by First Trust Portfolios L.P. and First Trust Advisors L.P. The Value Line Target 25, Value Line Target Safety 30, Target VIP, Target Focus Four and Target Double Play portfolios are not sponsored, endorsed, recommended, sold or promoted by Value Line and Value Line makes no representation regarding the advisability of investing in products utilizing such strategy. First Trust Portfolios L.P. and First Trust Advisors L.P. are not affiliated with any Value Line company.

The Nasdaq 100[®], Nasdaq 100 Index[®], and Nasdaq[®] are trade or service marks of Nasdaq, Inc. (which with its affiliates are the Corporations) and are licensed for use by First Trust Portfolios L.P. The Target VIP Portfolio has not been passed on by the Corporations as to its legality or suitability. The Target VIP Portfolio is not issued, endorsed, sold, or promoted by the Corporations. **THE CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THE PORTFOLIO.**